About Flotillin-1
Flotillin-1 (FLOT1) is a protein
from Homo sapiens identified by UniProt accession
O75955, 427 residues long.
MolForge cross-references it against 0 known binders and
118 disease associations.
Target properties
| Protein name | Flotillin-1 |
|---|
| UniProt accession | O75955 |
|---|
| Gene | FLOT1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 427 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (118)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.33
- thyroid gland adenocarcinoma · score 0.18
- chronic obstructive pulmonary disease · score 0.18
- smoking status measurement · score 0.15
- non-small cell lung carcinoma · score 0.08
- neoplasm · score 0.08
- lung adenocarcinoma · score 0.07
- colorectal cancer · score 0.06
- handedness · score 0.06
- age-related macular degeneration · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75955-F1 | alphafold | PREDICTED | 81.62 | — |
Amino-acid sequence (427 residues)
MFFTCGPNEA MVVSGFCRSP PVMVAGGRVF VLPCIQQIQR ISLNTLTLNV KSEKVYTRHG VPISVTGIAQ VKIQGQNKEM LAAACQMFLG KTEAEIAHIA LETLEGHQRA IMAHMTVEEI YKDRQKFSEQ VFKVASSDLV NMGISVVSYT LKDIHDDQDY LHSLGKARTA QVQKDARIGE AEAKRDAGIR EAKAKQEKVS AQYLSEIEMA KAQRDYELKK AAYDIEVNTR RAQADLAYQL QVAKTKQQIE EQRVQVQVVE RAQQVAVQEQ EIARREKELE ARVRKPAEAE RYKLERLAEA EKSQLIMQAE AEAASVRMRG EAEAFAIGAR ARAEAEQMAK KAEAFQLYQE AAQLDMLLEK LPQVAEEISG PLTSANKITL VSSGSGTMGA AKVTGEVLDI LTRLPESVER LTGVSISQVN HKPLRTA
Explore Flotillin-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets